Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cadila-Hetero Slugfest Over The 'Hep' Tag

Executive Summary

Trademark disputes continue unabated in Indian courts, this time involving generic versions of Bristol-Myers Squibb's hepatitis C therapy, Daklinza (daclatasvir) marketed by the local firms Cadila Healthcare and Hetero.

You may also be interested in...

Gilead Moves To Block Harvoni Infringer In India

Gilead Sciences has moved court to block an alleged copy of its blockbuster hepatitis C treatment, Harvoni (sofosbuvir/ledipasvir), in India which it believes not only wrongly rides on the brand name but may also not have the requisite regulatory approvals.

Generic Daklinza Deal Sets Precedent In HCV Drug Licensing

The licensing agreement announced on Nov. 23 by the Medicines Patent Pool and Bristol-Myers Squibb, under which generics firms will be able to manufacture their own versions of the firm's hepatitis C drug daclatasvir for sale in more than a hundred lower-income countries, breaks new ground in several different ways.

Novartis-Intas Ranibizumab Settlement Sets Liability For Breach

Novartis and Intas Pharmaceuticals Ltd have reached an out-of-court settlement pertaining to their dispute concerning ranibizumab.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts